funding

A US district court judge will soon rule on whether federal guidelines on human embryonic stem cell funding incentivize the destruction of embryos.

President Barack Obama turns to US academic institutions for innovation and job creation.

Today is your last chance to participate in our 2011 survey of life science salaries.

The US government's energy research efforts may be hobbled by budget cuts.

Wisconsin legislators amend a budget that would have banned high speed data-sharing networks.

Fifteen plant biologists are selected to take part in a new initiative in fundamental plant science research.

A proposed Wisconsin budget would bar state universities from sharing data through a high-speed network.

Take our survey to help us determine the most current salary data for life scientists.

The path to eradicating malaria in Africa involves much more than just a vaccine.

Successful vaccines have been created to protect against pathogenic bacteria and viruses. Why aren’t there any for combating fungal infections?

Decades of vaccine research have expanded our understanding of the immune system and are yielding novel disease-fighting tactics.

A major international funder of research and public health efforts on debilitating infectious diseases has frozen hundreds of millions of dollars in grant money to China amidst questions about the country's use of the funds. 

Ron Kaback didn’t believe that electrochemical gradients could power the transport of sugars and amino acids across cell membranes—until he proved that they do.

By forging new relationships and finding novel uses for existing technologies, this year’s top companies are employing creative ways to advance their science.

Counting the many plagues that threaten research in the Middle East and North Africa region

Setting up your own scientific laboratory is no easy task, but this year’s respondents are using their postdoc experiences to prepare for the challenge.

Secrets to scoring big money grants for innovative, out-of-the-box research

A selection of comments from our readers

Despite chill winds on Wall Street, investors continue to place bets on fledgling biotechnology companies.